Thilo Mengling

Dr. Thilo Mengling

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2020 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
TMThilo Mengling
Thilo Mengling
GRGabi Rall
Gabi Rall
SBStefanie N. Bernas
Stefanie N. Bernas
NANadia Astreou
Nadia Astreou
SBSandra Bochert
Sandra Bochert
ASAlexander H. Schmidt
Alexander H. Schmidt
The COVID-19 pandemic has serious implications also for patients with other diseases. Here, we describe the effects of the pandemic on unrelated hematopoietic stem cell donation and transplantation from the perspective of DKMS, a large international donor registry. Especially, we cover the development of PBSC and bone marrow collection figures, donor management including Health and Availability Check (HAC), transport and cryopreservation of stem cell products, donor recruitment and business continuity measures. The total number of stem cell products provided declined by around 15% during the crisis with a particularly strong decrease in bone marrow products. We modified donor management processes to ensure donor and product safety. HAC instead of confirmatory typing was helpful especially in countries with strict lockdowns. New transport modes were developed so that stem cell products could be safely delivered despite COVID-19-related travel restrictions. Cryopreservation of stem cell products became the new temporary standard during the pandemic to minimize risks related to transport logistics and donor availability. However, many products from unrelated donors will never be transfused. DKMS discontinued public offline donor recruitment, leading to a 40% decline in new donors during the crisis. Most DKMS employees worked from home to ensure business continuity during the crisis.

1 June 2017 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
ASAlexander H. Schmidt
Alexander H. Schmidt
TMThilo Mengling
Thilo Mengling
CHCamila J. Hernández-Frederick
Camila J. Hernández-Frederick
GRGabi Rall
Gabi Rall
JPJulia Pingel
Julia Pingel
GEGerhard Ehninger
Gerhard Ehninger
Donor safety is of utmost importance in the setting of hematopoietic stem cell donation. Follow-up is indicated to detect potential long-term risks for donors. We sent a follow-up questionnaire to 15,445 donors of peripheral blood stem cells (PBSCs) or bone marrow (BM) within a retrospective study design. The return rate was 91.3%, resulting in 37,287 observation years for PBSC donors and 25,656 for BM donors. Most donors assessed their health conditions as very good or good and had not been hospitalized or received long-term medical treatment including prescribed medication for more than 4 weeks since donation. Although there were no differences in the frequency of reported health events, BM donors more often rated their general health as very good or good. Ninety-five percent of donors after BM or PBSC donation would consider a second stem cell donation. In total, 93 malignancies were reported. The standardized incidence ratio (SIR) for a diagnosis of any type of cancer after PBSC donation was .94 (95% CI, .70 to 1.24) with a SIR below 1 indicating a lower risk than in the age- and sex-matched population. The SIR for a diagnosis of leukemia was 0 (95% CI, 0 to 1.88). In summary, we found no evidence that either PBSC or BM donation are associated with increased risks of malignancies or other severe health problems.

24 December 2020 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
ASAlexander H. Schmidt
Alexander H. Schmidt
DBDeborah Buk
Deborah Buk
SBStefanie N. Bernas
Stefanie N. Bernas
TMThilo Mengling
Thilo Mengling
ENElke Neujahr
Elke Neujahr
MBMarcel R. M. van Den Brink
Marcel R. M. van Den Brink
Click on the article title to read more.

26 September 2025 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
LFL. M. Foeken
L. M. Foeken
JFJ. A. Feinberg
J. A. Feinberg
JDJ. H. M. Dijkman
J. H. M. Dijkman
HEH.-P. R. Eberhard
H.-P. R. Eberhard
EEE. van Eerden
E. van Eerden
MSM. Seftel
M. Seftel

9 July 2016 in Hepatology
Verified
Journal Article
Closed access
PDF file
MPMichael Punzel
Michael Punzel
PMPatrick Medd
Patrick Medd
HHHannah Hunter
Hannah Hunter
RCRichard Cunningham
Richard Cunningham
BPBryson Pottinger
Bryson Pottinger
JVJens Verheyen
Jens Verheyen

23 January 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
TDTania Dexter
Tania Dexter
KPKalinga Perera
Kalinga Perera
ATAlejandra Martínez Trillos
Alejandra Martínez Trillos
JFJesus Fernandez-Sojo
Jesus Fernandez-Sojo
JWJane Ward
Jane Ward
MCMeghann Cody
Meghann Cody